{"id": "article-20356_0", "title": "Dentatorubral Pallidoluysian Atrophy -- Continuing Education Activity", "content": "Dentatorubral-pallidoluysian atrophy (DRPLA) is a progressive, autosomal dominant disorder with symptoms and severity that vary with the age of onset. Identifying cardinal features of adult and juvenile DRPLA can guide a neurologist towards diagnosis and supportive treatment of symptoms. Given the autosomal dominant inheritance, genetic counseling is important given the level of functional impairment caused by this disorder. This activity will highlight the importance of the interprofessional team in the evaluation and management of DRPLA, including post-diagnosis counseling and symptomatic management.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Continuing Education Activity. Dentatorubral-pallidoluysian atrophy (DRPLA) is a progressive, autosomal dominant disorder with symptoms and severity that vary with the age of onset. Identifying cardinal features of adult and juvenile DRPLA can guide a neurologist towards diagnosis and supportive treatment of symptoms. Given the autosomal dominant inheritance, genetic counseling is important given the level of functional impairment caused by this disorder. This activity will highlight the importance of the interprofessional team in the evaluation and management of DRPLA, including post-diagnosis counseling and symptomatic management."}
{"id": "article-20356_1", "title": "Dentatorubral Pallidoluysian Atrophy -- Continuing Education Activity", "content": "Objectives: Identify the etiology of dentatorubral-pallidoluysian atrophy. Describe the history and physical findings in patients with dentatorubral-pallidoluysian atrophy. Review the management options available for dentatorubral-pallidoluysian atrophy. Summarize the role of the interprofessional team in managing patients suffering from DRPLA. Access free multiple choice questions on this topic.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Continuing Education Activity. Objectives: Identify the etiology of dentatorubral-pallidoluysian atrophy. Describe the history and physical findings in patients with dentatorubral-pallidoluysian atrophy. Review the management options available for dentatorubral-pallidoluysian atrophy. Summarize the role of the interprofessional team in managing patients suffering from DRPLA. Access free multiple choice questions on this topic."}
{"id": "article-20356_2", "title": "Dentatorubral Pallidoluysian Atrophy -- Introduction", "content": "Dentatorubral-pallidoluysian atrophy (DRPLA) is a progressive autosomal dominant disorder characterized by myoclonic epilepsy, ataxia, choreoathetosis/dystonia, cognitive impairment/dementia, and psychiatric disturbances. [1] [2] [3] [4] [5] [4] [3] [1] Rarely, corneal endothelial degeneration, head tremor, or optic atrophy\u00a0may be present. [6] [7] [8] [7] [6] The presentation varies with the age of onset. The disorder was first described in 1946,\u00a0and the name was given in1958. [9] [10] [9]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Introduction. Dentatorubral-pallidoluysian atrophy (DRPLA) is a progressive autosomal dominant disorder characterized by myoclonic epilepsy, ataxia, choreoathetosis/dystonia, cognitive impairment/dementia, and psychiatric disturbances. [1] [2] [3] [4] [5] [4] [3] [1] Rarely, corneal endothelial degeneration, head tremor, or optic atrophy\u00a0may be present. [6] [7] [8] [7] [6] The presentation varies with the age of onset. The disorder was first described in 1946,\u00a0and the name was given in1958. [9] [10] [9]"}
{"id": "article-20356_3", "title": "Dentatorubral Pallidoluysian Atrophy -- Etiology", "content": "Dentatorubral-pallidoluysian atrophy is a cytosine, adenine, and guanine (CAG) trinucleotide repeat expansion in the atrophin-1 (ATN1) gene, in exon 5. [3] [11] This gene on chromosome 12p13.31, encodes a transcriptional co-repressor expressed in the central nervous system (CNS) and other organs in the body. [12] Normal CAG repeats range between 6-35. Pathogenic\u00a0CAG repeat length can range from 48 to 93, with higher repeat length correlated with worse disease severity, in most cases. [13] [14]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Etiology. Dentatorubral-pallidoluysian atrophy is a cytosine, adenine, and guanine (CAG) trinucleotide repeat expansion in the atrophin-1 (ATN1) gene, in exon 5. [3] [11] This gene on chromosome 12p13.31, encodes a transcriptional co-repressor expressed in the central nervous system (CNS) and other organs in the body. [12] Normal CAG repeats range between 6-35. Pathogenic\u00a0CAG repeat length can range from 48 to 93, with higher repeat length correlated with worse disease severity, in most cases. [13] [14]"}
{"id": "article-20356_4", "title": "Dentatorubral Pallidoluysian Atrophy -- Etiology", "content": "Some exceptions are\u00a0reported in rare cases of asymptomatic patients with high CAG repeats. Complete penetrance of the condition is more than 48 tandem copies, which have a typical clinical presentation. Incomplete penetrance phenotypes are\u00a0found in patients with alleles of 35\u00a0to 47 repeat length, associated with a milder clinical phenotype.\u00a0Japanese patients have a higher number of baseline CAG repeats, 20\u00a0to 35, compared to people of European\u00a0descent. [15] [16] The clinical-genetic phenomenology of non-Asian DRPLA is similar to the Asian DRPLA. [17]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Etiology. Some exceptions are\u00a0reported in rare cases of asymptomatic patients with high CAG repeats. Complete penetrance of the condition is more than 48 tandem copies, which have a typical clinical presentation. Incomplete penetrance phenotypes are\u00a0found in patients with alleles of 35\u00a0to 47 repeat length, associated with a milder clinical phenotype.\u00a0Japanese patients have a higher number of baseline CAG repeats, 20\u00a0to 35, compared to people of European\u00a0descent. [15] [16] The clinical-genetic phenomenology of non-Asian DRPLA is similar to the Asian DRPLA. [17]"}
{"id": "article-20356_5", "title": "Dentatorubral Pallidoluysian Atrophy -- Epidemiology", "content": "Dentatorubral-pallidoluysian atrophy has a median age of onset of\u00a031 years of age. It mainly affects\u00a0Asian populations, in particular, the Japanese population. The\u00a0incidence\u00a0is approximately 2\u00a0to 7 per million people in the Japanese population. [12] [18] The prevalence of DRPLA in Japanese people has been estimated to be 0.2 to 0.4 per 100,000. [19] Although DRPLA was initially recognized in Asian populations, wider genetic testing has increased diagnosis in other ethnic groups/families. [17] [20] [21] [22] [23] [24]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Epidemiology. Dentatorubral-pallidoluysian atrophy has a median age of onset of\u00a031 years of age. It mainly affects\u00a0Asian populations, in particular, the Japanese population. The\u00a0incidence\u00a0is approximately 2\u00a0to 7 per million people in the Japanese population. [12] [18] The prevalence of DRPLA in Japanese people has been estimated to be 0.2 to 0.4 per 100,000. [19] Although DRPLA was initially recognized in Asian populations, wider genetic testing has increased diagnosis in other ethnic groups/families. [17] [20] [21] [22] [23] [24]"}
{"id": "article-20356_6", "title": "Dentatorubral Pallidoluysian Atrophy -- Epidemiology", "content": "When worldwide DRPLA cases are counted for among the spinocerebellar ataxia (SCA), the rate in the Japanese population is 7\u00a0to 20%, with lower rates in other Asian populations (Singapore, 6%; Korea, 3%),\u00a0Portuguese families 2\u00a0to 4%, other European descent 0.25\u00a0to 1%,\u00a0and Latin-American families 0.14\u00a0to 3.1%. [15] It equally affects men and women. Juveline-onset disease or\u00a0progressive myoclonic epilepsy (PME) phenotype patients (less than 20 years of age), typically present with seizures and some form of neurodevelopment disorder.\u00a0Genotypically, they have longer CAG repeat lengths ( more than 65), and they have generalized seizures and myoclonus with progressive intellectual disability. [15] Adult-onset or without PME phenotype (more than 20 years of age),\u00a0on the\u00a0other hand, has symptoms that include ataxia, choreoathetosis, cognitive impairment, dementia, and psychiatric features. Additionally, they have shorter CAG repeat lengths (less than 65), with seizures being a rare symptom.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Epidemiology. When worldwide DRPLA cases are counted for among the spinocerebellar ataxia (SCA), the rate in the Japanese population is 7\u00a0to 20%, with lower rates in other Asian populations (Singapore, 6%; Korea, 3%),\u00a0Portuguese families 2\u00a0to 4%, other European descent 0.25\u00a0to 1%,\u00a0and Latin-American families 0.14\u00a0to 3.1%. [15] It equally affects men and women. Juveline-onset disease or\u00a0progressive myoclonic epilepsy (PME) phenotype patients (less than 20 years of age), typically present with seizures and some form of neurodevelopment disorder.\u00a0Genotypically, they have longer CAG repeat lengths ( more than 65), and they have generalized seizures and myoclonus with progressive intellectual disability. [15] Adult-onset or without PME phenotype (more than 20 years of age),\u00a0on the\u00a0other hand, has symptoms that include ataxia, choreoathetosis, cognitive impairment, dementia, and psychiatric features. Additionally, they have shorter CAG repeat lengths (less than 65), with seizures being a rare symptom."}
{"id": "article-20356_7", "title": "Dentatorubral Pallidoluysian Atrophy -- Pathophysiology", "content": "Dentatorubral-pallidoluysian atrophy is one of the CAG repeat disorders that show atrophin-1 protein deposition in the nucleus of affected neurons, known as neuronal intranuclear inclusion (NII).\u00a0Polyglutamine (poly-Q) expansion characterizes autosomal-dominant neurodegenerative disorders such as Huntington disease (HD),\u00a0and six of the spinocerebellar ataxia (SCA) disorders, which could be an important pathogenic feature in common with DRPLA and may explain the\u00a0genetic anticipation and de novo expansion. [25] [26] [27] [28]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Pathophysiology. Dentatorubral-pallidoluysian atrophy is one of the CAG repeat disorders that show atrophin-1 protein deposition in the nucleus of affected neurons, known as neuronal intranuclear inclusion (NII).\u00a0Polyglutamine (poly-Q) expansion characterizes autosomal-dominant neurodegenerative disorders such as Huntington disease (HD),\u00a0and six of the spinocerebellar ataxia (SCA) disorders, which could be an important pathogenic feature in common with DRPLA and may explain the\u00a0genetic anticipation and de novo expansion. [25] [26] [27] [28]"}
{"id": "article-20356_8", "title": "Dentatorubral Pallidoluysian Atrophy -- Pathophysiology", "content": "Lysine-specific demethylase 1 (LSD1) and its target ATN1 may be responsible for neuronal pluripotent development of cells in the cortex. [29] Animal models suggest that NII occurs without completed apoptosis, leading to poor clearance of aggregated polyQ inclusions. [30] It is still unclear whether the inclusion is a pathogenic feature, or a\u00a0failed neuroprotective process, such as seen in HD. [26] [31] [32]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Pathophysiology. Lysine-specific demethylase 1 (LSD1) and its target ATN1 may be responsible for neuronal pluripotent development of cells in the cortex. [29] Animal models suggest that NII occurs without completed apoptosis, leading to poor clearance of aggregated polyQ inclusions. [30] It is still unclear whether the inclusion is a pathogenic feature, or a\u00a0failed neuroprotective process, such as seen in HD. [26] [31] [32]"}
{"id": "article-20356_9", "title": "Dentatorubral Pallidoluysian Atrophy -- Pathophysiology", "content": "Antibody mediated-immunohistochemistry, in DRPLA post-mortem brains,\u00a0shows polyglutamine protein structures or stretches that co-deposit with a mutant and insoluble ATN1 protein as part of a diffuse intraneuronal accumulation in densely packed areas within the NII. The dominant hypothesis is\u00a0that the number of NII correlates with clinical features such as dementia and epilepsy, with neuropathological studies showing reduced\u00a0number and size of spines and diameter of dendrites. All these findings could explain the brain atrophy\u00a0seen in neuroimaging. [15]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Pathophysiology. Antibody mediated-immunohistochemistry, in DRPLA post-mortem brains,\u00a0shows polyglutamine protein structures or stretches that co-deposit with a mutant and insoluble ATN1 protein as part of a diffuse intraneuronal accumulation in densely packed areas within the NII. The dominant hypothesis is\u00a0that the number of NII correlates with clinical features such as dementia and epilepsy, with neuropathological studies showing reduced\u00a0number and size of spines and diameter of dendrites. All these findings could explain the brain atrophy\u00a0seen in neuroimaging. [15]"}
{"id": "article-20356_10", "title": "Dentatorubral Pallidoluysian Atrophy -- Histopathology", "content": "Post-mortem studies of the patients suffering from dentatorubral-pallidoluysian atrophy show interesting features including atrophy in the entire spinal cord neuraxis, neuronal apoptosis, and astrocytosis in the dentatorubral and pallidoluysian systems (globus pallidus, red nucleus, and to a lesser degree, the dentate nucleus and subthalamic nucleus). It can cause severe diffuse cortical white matter disease. Frontal lobe and pontine atrophy are present in the juvenile-onset cases, characterized by a severe clinical phenotype with cognitive deterioration and seizures. Interestingly,\u00a0hippocampal regions are relatively spared.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Histopathology. Post-mortem studies of the patients suffering from dentatorubral-pallidoluysian atrophy show interesting features including atrophy in the entire spinal cord neuraxis, neuronal apoptosis, and astrocytosis in the dentatorubral and pallidoluysian systems (globus pallidus, red nucleus, and to a lesser degree, the dentate nucleus and subthalamic nucleus). It can cause severe diffuse cortical white matter disease. Frontal lobe and pontine atrophy are present in the juvenile-onset cases, characterized by a severe clinical phenotype with cognitive deterioration and seizures. Interestingly,\u00a0hippocampal regions are relatively spared."}
{"id": "article-20356_11", "title": "Dentatorubral Pallidoluysian Atrophy -- Histopathology", "content": "Chemical staining for protein structures encoded by a mutant ATN1 protein shows poly-Q deposition of\u00a0diffuse intraneuronal accumulation within the nucleus of affected neurons. The latter are spherical, eosinophilic non-membrane bound structures that contain a mixture of granular and filamentous ubiquitinated structures, containing inclusions of the mutant ATN1 protein. [15] [33] [34]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Histopathology. Chemical staining for protein structures encoded by a mutant ATN1 protein shows poly-Q deposition of\u00a0diffuse intraneuronal accumulation within the nucleus of affected neurons. The latter are spherical, eosinophilic non-membrane bound structures that contain a mixture of granular and filamentous ubiquitinated structures, containing inclusions of the mutant ATN1 protein. [15] [33] [34]"}
{"id": "article-20356_12", "title": "Dentatorubral Pallidoluysian Atrophy -- History and Physical", "content": "Clinical diagnosis of dentatorubral-pallidoluysian atrophy is challenging, given\u00a0heterogeneous phenotypes and similarities to spinocerebellar ataxias.\u00a0Symptoms and neuroimaging vary according to the age of onset. Late-onset DRPLA can sometimes present as isolated cerebellar ataxia, or dementia. [15] When it begins before the age of 20 it\u00a0typically exhibits: Myoclonus Seizures of different types Behavioral changes Progressive intellectual disability and deterioration Ataxia When it begins after the age of 20 years it presents with: Ataxia Choreoathetosis or dystonia Psychiatric symptoms (delusions) Dementia Rarely, head tremors and visual problems Exam findings include neurocognitive\u00a0impairment\u00a0on executive function, language, memory, dysmetria, cerebellar ataxia, motor weakness, upper motor neuron signs, and difficulties with gait.", "contents": "Dentatorubral Pallidoluysian Atrophy -- History and Physical. Clinical diagnosis of dentatorubral-pallidoluysian atrophy is challenging, given\u00a0heterogeneous phenotypes and similarities to spinocerebellar ataxias.\u00a0Symptoms and neuroimaging vary according to the age of onset. Late-onset DRPLA can sometimes present as isolated cerebellar ataxia, or dementia. [15] When it begins before the age of 20 it\u00a0typically exhibits: Myoclonus Seizures of different types Behavioral changes Progressive intellectual disability and deterioration Ataxia When it begins after the age of 20 years it presents with: Ataxia Choreoathetosis or dystonia Psychiatric symptoms (delusions) Dementia Rarely, head tremors and visual problems Exam findings include neurocognitive\u00a0impairment\u00a0on executive function, language, memory, dysmetria, cerebellar ataxia, motor weakness, upper motor neuron signs, and difficulties with gait."}
{"id": "article-20356_13", "title": "Dentatorubral Pallidoluysian Atrophy -- Evaluation", "content": "There are no clinical diagnostic criteria for dentatorubral-pallidoluysian atrophy. Clinical symptoms,\u00a0family history, and ancestry can increase the yield of the targeted\u00a0molecular genetic testing. [35] [36] Genetic testing\u00a0consists of a polymerase chain reaction (PCR) amplification across the ATN1 CAG repeat region. To increase the sensitivity of the test in higher CAG repeats, a capillary electrophoresis-Southern Blot is used to confirm the diagnosis.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Evaluation. There are no clinical diagnostic criteria for dentatorubral-pallidoluysian atrophy. Clinical symptoms,\u00a0family history, and ancestry can increase the yield of the targeted\u00a0molecular genetic testing. [35] [36] Genetic testing\u00a0consists of a polymerase chain reaction (PCR) amplification across the ATN1 CAG repeat region. To increase the sensitivity of the test in higher CAG repeats, a capillary electrophoresis-Southern Blot is used to confirm the diagnosis."}
{"id": "article-20356_14", "title": "Dentatorubral Pallidoluysian Atrophy -- Evaluation", "content": "Although whole-genome sequencing technologies are promising, they lack internal and external\u00a0validation for CAG expansion specific for DRPLA. An electroencephalogram (EEG) is used to guide management in the context of\u00a0suspicion of seizures. Focal motor seizures with impaired awareness progressing to generalized tonic-clonic seizures are the typical semiology. [37] [38] Brain magnetic resonance imaging (MRI) can show diffuse cerebellar and brainstem atrophy, diffuse periventricular white matter disease, but these are mostly non-specific. [39] [40] [41] [42] [43] [44]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Evaluation. Although whole-genome sequencing technologies are promising, they lack internal and external\u00a0validation for CAG expansion specific for DRPLA. An electroencephalogram (EEG) is used to guide management in the context of\u00a0suspicion of seizures. Focal motor seizures with impaired awareness progressing to generalized tonic-clonic seizures are the typical semiology. [37] [38] Brain magnetic resonance imaging (MRI) can show diffuse cerebellar and brainstem atrophy, diffuse periventricular white matter disease, but these are mostly non-specific. [39] [40] [41] [42] [43] [44]"}
{"id": "article-20356_15", "title": "Dentatorubral Pallidoluysian Atrophy -- Evaluation", "content": "Hypoalbuminemia has also been studied as a possible biological marker, given that some studies show it is inversely correlated with CAG length. [15] [45] Although\u00a0next-generation sequencing technologies are promising,\u00a0they have not been widely used or validated\u00a0for the ATN1 repeat expansion.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Evaluation. Hypoalbuminemia has also been studied as a possible biological marker, given that some studies show it is inversely correlated with CAG length. [15] [45] Although\u00a0next-generation sequencing technologies are promising,\u00a0they have not been widely used or validated\u00a0for the ATN1 repeat expansion."}
{"id": "article-20356_16", "title": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management", "content": "Unfortunately, there is no\u00a0cure for dentatorubral-pallidoluysian atrophy. Treatment is predominantly supportive. Genetic counseling of patients and their family members is essential given that the condition is autosomal dominant, with important ethical considerations before diagnosis disclosure.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management. Unfortunately, there is no\u00a0cure for dentatorubral-pallidoluysian atrophy. Treatment is predominantly supportive. Genetic counseling of patients and their family members is essential given that the condition is autosomal dominant, with important ethical considerations before diagnosis disclosure."}
{"id": "article-20356_17", "title": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management", "content": "When there is clinical suspicion of seizures; selecting an anti-epileptic drug (AED) could be individualized to the predominant clinical scenario of the seizures. No AED is found superior to others in randomized controlled studies. However, levetiracetam and perampanel\u00a0show promise in juvenile-onset DRPLA. [38] [46] [47] Choreoathetoid and dystonic movements are treated with tetrabenazine, risperidone, and gabapentin. [42] [48] Consensus European guidelines show that riluzole (Class B evidence) or amantadine (Class\u00a0C evidence) can potentially improve ataxic symptoms. [49] [50] [51] [52] Given unknown teratogenicity, however, they are avoided in childbearing patients or currently pregnant patients.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management. When there is clinical suspicion of seizures; selecting an anti-epileptic drug (AED) could be individualized to the predominant clinical scenario of the seizures. No AED is found superior to others in randomized controlled studies. However, levetiracetam and perampanel\u00a0show promise in juvenile-onset DRPLA. [38] [46] [47] Choreoathetoid and dystonic movements are treated with tetrabenazine, risperidone, and gabapentin. [42] [48] Consensus European guidelines show that riluzole (Class B evidence) or amantadine (Class\u00a0C evidence) can potentially improve ataxic symptoms. [49] [50] [51] [52] Given unknown teratogenicity, however, they are avoided in childbearing patients or currently pregnant patients."}
{"id": "article-20356_18", "title": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management", "content": "A neuropsychological and psychiatric assessment is instrumental for evaluating major neurocognitive deficits and associated mood disorders, for enhanced quality of life. Physical and occupational therapy is important to maintain functional activities of daily living. Structured and individualized\u00a0educational programs for children with the disease is another important consideration. Involving an interprofessional team of providers can help address all the co-morbidities associated with the disorder and enhance the number of quality life years. Avoiding general anesthesia during surgical procedures can decrease the rate of breakthrough seizures. [15]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management. A neuropsychological and psychiatric assessment is instrumental for evaluating major neurocognitive deficits and associated mood disorders, for enhanced quality of life. Physical and occupational therapy is important to maintain functional activities of daily living. Structured and individualized\u00a0educational programs for children with the disease is another important consideration. Involving an interprofessional team of providers can help address all the co-morbidities associated with the disorder and enhance the number of quality life years. Avoiding general anesthesia during surgical procedures can decrease the rate of breakthrough seizures. [15]"}
{"id": "article-20356_19", "title": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management", "content": "CAG repeat expansion disorder and developments in transcription silencing is a promising venue for curative treatment. This is currently used for SCA and HD with some success in animal\u00a0models. Ribonucleic acid (RNA) interference of multiple alleles is possible within the CNS, although it is costly and time-consuming, and still in an experimental phase. Another promising strategy is to use targeted RNA small molecules that affect the translation of mutant ATN-1 and has the advantage of crossing the blood-brain barrier. Challenges include poor absorption and allergic reactions. [15] [53] [54] [55] [56]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Treatment / Management. CAG repeat expansion disorder and developments in transcription silencing is a promising venue for curative treatment. This is currently used for SCA and HD with some success in animal\u00a0models. Ribonucleic acid (RNA) interference of multiple alleles is possible within the CNS, although it is costly and time-consuming, and still in an experimental phase. Another promising strategy is to use targeted RNA small molecules that affect the translation of mutant ATN-1 and has the advantage of crossing the blood-brain barrier. Challenges include poor absorption and allergic reactions. [15] [53] [54] [55] [56]"}
{"id": "article-20356_20", "title": "Dentatorubral Pallidoluysian Atrophy -- Differential Diagnosis", "content": "The diagnosis of dentatorubral-pallidoluysian atrophy is challenging without a known family history of the disease. Clinical symptoms can mimic other familial degenerative or acquired ataxic disorders.\u00a0An extensive metabolic and genetic workup can be helpful if the diagnosis is unclear. Advanced imaging, along with cerebrospinal fluid and serum studies, may also help rule out other disorders. [15] [40] [57] Differential diagnoses for adult-onset DRPLA include: Huntington disease Spinocerebellar ataxia Atypical parkinsonism with cerebellar ataxia Alcohol Toxic/metabolic induced ataxias Ataxic paraneoplastic syndromes Differentials for juvenile-onset DRPLA are broad and include:", "contents": "Dentatorubral Pallidoluysian Atrophy -- Differential Diagnosis. The diagnosis of dentatorubral-pallidoluysian atrophy is challenging without a known family history of the disease. Clinical symptoms can mimic other familial degenerative or acquired ataxic disorders.\u00a0An extensive metabolic and genetic workup can be helpful if the diagnosis is unclear. Advanced imaging, along with cerebrospinal fluid and serum studies, may also help rule out other disorders. [15] [40] [57] Differential diagnoses for adult-onset DRPLA include: Huntington disease Spinocerebellar ataxia Atypical parkinsonism with cerebellar ataxia Alcohol Toxic/metabolic induced ataxias Ataxic paraneoplastic syndromes Differentials for juvenile-onset DRPLA are broad and include:"}
{"id": "article-20356_21", "title": "Dentatorubral Pallidoluysian Atrophy -- Differential Diagnosis", "content": "Familial essential myoclonus and epilepsy Progressive myoclonic epilepsy Lafora disease Unverricht-Lundborg disease Infantile neuroaxonal dystrophy Neuroferritinopathy Myoclonus epilepsy associated with ragged red fibers Heoxosaminidase A deficiency Neuronal ceroid-lipofuscinosis Gaucher disease Sialidosis Galactosialidosis", "contents": "Dentatorubral Pallidoluysian Atrophy -- Differential Diagnosis. Familial essential myoclonus and epilepsy Progressive myoclonic epilepsy Lafora disease Unverricht-Lundborg disease Infantile neuroaxonal dystrophy Neuroferritinopathy Myoclonus epilepsy associated with ragged red fibers Heoxosaminidase A deficiency Neuronal ceroid-lipofuscinosis Gaucher disease Sialidosis Galactosialidosis"}
{"id": "article-20356_22", "title": "Dentatorubral Pallidoluysian Atrophy -- Prognosis", "content": "As there is no cure for dentatorubral-pallidoluysian atrophy, the mean\u00a0age at death is 49 years (range 18\u201380 years); the median time from disease onset to death is 15 years. [13] The length of the CAG repeat expansion in ATN1 is positively correlated with age of onset, clinical symptoms, and longevity, with more than 48 repeats being linked to early-onset, severe disease phenotype, and a shorter lifespan. Functional impairment is also inversely correlated with CAG repeat length and lead to a poorer quality of life years and higher disability burden. [13] Unfortunately,\u00a0DRPLA is classified as a microsatellite repeat disorder, which shows genetic anticipation with earlier onset and worse disease severity as it passes to the next generation of offsprings. [15]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Prognosis. As there is no cure for dentatorubral-pallidoluysian atrophy, the mean\u00a0age at death is 49 years (range 18\u201380 years); the median time from disease onset to death is 15 years. [13] The length of the CAG repeat expansion in ATN1 is positively correlated with age of onset, clinical symptoms, and longevity, with more than 48 repeats being linked to early-onset, severe disease phenotype, and a shorter lifespan. Functional impairment is also inversely correlated with CAG repeat length and lead to a poorer quality of life years and higher disability burden. [13] Unfortunately,\u00a0DRPLA is classified as a microsatellite repeat disorder, which shows genetic anticipation with earlier onset and worse disease severity as it passes to the next generation of offsprings. [15]"}
{"id": "article-20356_23", "title": "Dentatorubral Pallidoluysian Atrophy -- Complications", "content": "Many complications can arise from the comorbidity that comes with dentatorubral-pallidoluysian atrophy. Following are some of the complications such patients can have: Progressive repetitive seizures Status epilepticus Solid/liquid dysphagia with potential aspiration pneumonia [13]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Complications. Many complications can arise from the comorbidity that comes with dentatorubral-pallidoluysian atrophy. Following are some of the complications such patients can have: Progressive repetitive seizures Status epilepticus Solid/liquid dysphagia with potential aspiration pneumonia [13]"}
{"id": "article-20356_24", "title": "Dentatorubral Pallidoluysian Atrophy -- Consultations", "content": "As dentatorubral-pallidoluysian atrophy is a disorder involving the neuromuscular system of the patient it requires input from an interprofessional team. This team may comprise of the following: Adult or pediatric neurologists Epilepsy neurologists Geriatrics Pediatrics Geneticists Physical and occupational therapists Social workers Psychiatrists/psychologists Palliative medicine", "contents": "Dentatorubral Pallidoluysian Atrophy -- Consultations. As dentatorubral-pallidoluysian atrophy is a disorder involving the neuromuscular system of the patient it requires input from an interprofessional team. This team may comprise of the following: Adult or pediatric neurologists Epilepsy neurologists Geriatrics Pediatrics Geneticists Physical and occupational therapists Social workers Psychiatrists/psychologists Palliative medicine"}
{"id": "article-20356_25", "title": "Dentatorubral Pallidoluysian Atrophy -- Deterrence and Patient Education", "content": "Dentatorubral-pallidoluysian atrophy is a significant and severe disease affecting parents and children of affected parents. Exhaustive counseling is needed for both generations. It is a hereditary disorder whose symptoms vary depending on whether they begin in childhood or adulthood. A parent with the disease has a 50% chance of passing it to their children, regardless of sex or gender; therefore,\u00a0genetic counseling is important.\u00a0It involves excessive protein deposition\u00a0in the cells of the CNS, causing dysfunction and leading to the death of brain cells.\u00a0There is no cure for this disorder.\u00a0Prognosis is poor,\u00a0mean disease duration is about 15 years, and life expectancy\u00a08\u00a0to 16 years from symptom onset.\u00a0Early recognition of the disorder may improve patient understanding, and access to services and treatments.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Deterrence and Patient Education. Dentatorubral-pallidoluysian atrophy is a significant and severe disease affecting parents and children of affected parents. Exhaustive counseling is needed for both generations. It is a hereditary disorder whose symptoms vary depending on whether they begin in childhood or adulthood. A parent with the disease has a 50% chance of passing it to their children, regardless of sex or gender; therefore,\u00a0genetic counseling is important.\u00a0It involves excessive protein deposition\u00a0in the cells of the CNS, causing dysfunction and leading to the death of brain cells.\u00a0There is no cure for this disorder.\u00a0Prognosis is poor,\u00a0mean disease duration is about 15 years, and life expectancy\u00a08\u00a0to 16 years from symptom onset.\u00a0Early recognition of the disorder may improve patient understanding, and access to services and treatments."}
{"id": "article-20356_26", "title": "Dentatorubral Pallidoluysian Atrophy -- Deterrence and Patient Education -- Support Resources for Affected Patients and Families", "content": "Seek a healthcare specialist for medical advice, you can find them through advocacy organizations, academic medical centers, clinical trials, or medical peer-reviewed articles published in medical journals. If unable to find a specialist in your local area, contact national or international specialists. Global organizations supporting this disease include the National Ataxia Foundation, Ataxia UK, European Federation of Hereditary Ataxias, Epilepsy Foundation, and RareConnect.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Deterrence and Patient Education -- Support Resources for Affected Patients and Families. Seek a healthcare specialist for medical advice, you can find them through advocacy organizations, academic medical centers, clinical trials, or medical peer-reviewed articles published in medical journals. If unable to find a specialist in your local area, contact national or international specialists. Global organizations supporting this disease include the National Ataxia Foundation, Ataxia UK, European Federation of Hereditary Ataxias, Epilepsy Foundation, and RareConnect."}
{"id": "article-20356_27", "title": "Dentatorubral Pallidoluysian Atrophy -- Pearls and Other Issues", "content": "Dentatorubral-pallidoluysian atrophy is a progressive, autosomal dominant CAG repeat disorder typically characterized by\u00a0ataxia, myoclonus, epilepsy, choreoathetosis, dementia, psychiatric disturbance, and progressive intellectual deterioration. Juvenile onset (less than 20 years) disease presents with progressive myoclonus epilepsy disorder with ataxia and abnormal intellectual development, with recurrent severe seizures. The sudden unexpected death of someone with epilepsy (SUDEP) is the most deadly complication. Adult-onset (more than 20 years) disease presents with dystonias, neurocognitive and neuropsychiatric decline with ataxia, with aspiration pneumonia as the most common cause of mortality. DRPLA is a microsatellite CAG repeat disorder with genetic anticipation affecting the atrophin-1 (ATN1) gene, leading to the intranuclear accumulation of protein deposits in affected neurons, ultimately leading to progressive neuronal dysfunction, atrophy, and death.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Pearls and Other Issues. Dentatorubral-pallidoluysian atrophy is a progressive, autosomal dominant CAG repeat disorder typically characterized by\u00a0ataxia, myoclonus, epilepsy, choreoathetosis, dementia, psychiatric disturbance, and progressive intellectual deterioration. Juvenile onset (less than 20 years) disease presents with progressive myoclonus epilepsy disorder with ataxia and abnormal intellectual development, with recurrent severe seizures. The sudden unexpected death of someone with epilepsy (SUDEP) is the most deadly complication. Adult-onset (more than 20 years) disease presents with dystonias, neurocognitive and neuropsychiatric decline with ataxia, with aspiration pneumonia as the most common cause of mortality. DRPLA is a microsatellite CAG repeat disorder with genetic anticipation affecting the atrophin-1 (ATN1) gene, leading to the intranuclear accumulation of protein deposits in affected neurons, ultimately leading to progressive neuronal dysfunction, atrophy, and death."}
{"id": "article-20356_28", "title": "Dentatorubral Pallidoluysian Atrophy -- Pearls and Other Issues", "content": "Pathogenic\u00a0CAG repeat length can range from 48 to 93. Complete penetrance has 48 tandem copies, incomplete penetrance clinical phenotype has 35\u201347, and normal is less than 35. Japanese patients have a higher baseline of CAG repeats (20-35) compared to individuals from European\u00a0descent, which could explain their increased susceptibility to the disease.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Pearls and Other Issues. Pathogenic\u00a0CAG repeat length can range from 48 to 93. Complete penetrance has 48 tandem copies, incomplete penetrance clinical phenotype has 35\u201347, and normal is less than 35. Japanese patients have a higher baseline of CAG repeats (20-35) compared to individuals from European\u00a0descent, which could explain their increased susceptibility to the disease."}
{"id": "article-20356_29", "title": "Dentatorubral Pallidoluysian Atrophy -- Pearls and Other Issues", "content": "Prognosis is poor,\u00a0mean disease duration is about 15 years, and life expectancy is 8\u201316 years from symptom onset. The length of the ATN1 CAG repeat expansion is directly correlated with the age of onset, clinical phenotype, and life expectancy. Highly suspicious cases for DRPLA are further evaluated by targeted\u00a0molecular genetic testing: PCR amplification across the ATN1 CAG repeat region; for higher CAG repeats, ancillary Southern Blot electrophoresis, is used to confirm the diagnosis. EEG and MRI are helpful for certain clinical scenarios, but they are mostly non-specific for the disorder. Treatment is predominantly supportive: symptomatic treatment of seizures, ataxias, choreoathetosis, as well as nonpharmacological interventions such as special education programs for children, neurorehabilitation, neuropsychological and neuropsychiatric, and most importantly, genetic counseling. Avoiding general anesthesia during surgical procedures can decrease the rate of breakthrough seizures.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Pearls and Other Issues. Prognosis is poor,\u00a0mean disease duration is about 15 years, and life expectancy is 8\u201316 years from symptom onset. The length of the ATN1 CAG repeat expansion is directly correlated with the age of onset, clinical phenotype, and life expectancy. Highly suspicious cases for DRPLA are further evaluated by targeted\u00a0molecular genetic testing: PCR amplification across the ATN1 CAG repeat region; for higher CAG repeats, ancillary Southern Blot electrophoresis, is used to confirm the diagnosis. EEG and MRI are helpful for certain clinical scenarios, but they are mostly non-specific for the disorder. Treatment is predominantly supportive: symptomatic treatment of seizures, ataxias, choreoathetosis, as well as nonpharmacological interventions such as special education programs for children, neurorehabilitation, neuropsychological and neuropsychiatric, and most importantly, genetic counseling. Avoiding general anesthesia during surgical procedures can decrease the rate of breakthrough seizures."}
{"id": "article-20356_30", "title": "Dentatorubral Pallidoluysian Atrophy -- Enhancing Healthcare Team Outcomes", "content": "An interprofessional team that provides a holistic and integrated approach is important\u00a0in patients with DRPLA,\u00a0to reach diagnosis sooner, provide symptomatic control of co-morbidities, maximize life expectancy and the quality of life for patients with this devastating disorder. [58] Collaborative patient-centered decision-making and coordination of care between primary providers and subspecialists are essential to avoid gaps in care and improve health outcomes.\u00a0Education, physiotherapy, occupational therapy, genetic counseling, and environmental\u00a0adaptation may also be needed at different disease stages. Serious complications may need to be addressed in an intensive care unit. Palliative care can be considered\u00a0during the late stages of the disease. [59] [60] [61] [62] [63] [Level 1]", "contents": "Dentatorubral Pallidoluysian Atrophy -- Enhancing Healthcare Team Outcomes. An interprofessional team that provides a holistic and integrated approach is important\u00a0in patients with DRPLA,\u00a0to reach diagnosis sooner, provide symptomatic control of co-morbidities, maximize life expectancy and the quality of life for patients with this devastating disorder. [58] Collaborative patient-centered decision-making and coordination of care between primary providers and subspecialists are essential to avoid gaps in care and improve health outcomes.\u00a0Education, physiotherapy, occupational therapy, genetic counseling, and environmental\u00a0adaptation may also be needed at different disease stages. Serious complications may need to be addressed in an intensive care unit. Palliative care can be considered\u00a0during the late stages of the disease. [59] [60] [61] [62] [63] [Level 1]"}
{"id": "article-20356_31", "title": "Dentatorubral Pallidoluysian Atrophy -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Dentatorubral Pallidoluysian Atrophy -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}